Sodium-glucose cotransporter 2 (SGLT2) is a key glucose transporter protein in the kidney that accounts for nearly 90% of glucose reabsorption from primary urine, and SGLT2 inhibitors are novel oral drugs for the treatment of T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.